Clinical Chemistry Case Studies: Interpreting Results and Diagnosing Disorders

Clinical chemistry case studies train laboratory professionals to move from raw numerical results to defensible diagnostic conclusions. This article presents a structured method for working through patient histories, laboratory findings, and differential diagnoses using decision trees, reference interval awareness, and quality control principles. The content is designed for laboratory students, technicians, researchers, and diagnostic professionals who want to practice interpretation skills through realistic scenarios grounded in published evidence.

The Role of Case Studies in Clinical Chemistry Education

Case-based learning has demonstrated measurable value in diagnostic education. A survey of pharmacy students found that 88 percent of participating second-year students and 92 percent of participating third-year students reported that case studies enhanced their learning and appreciation for medicinal chemistry [9]. The same principle applies to clinical chemistry. Working through patient scenarios builds the critical thinking skills needed to connect laboratory values with pathophysiological states.

The Clinical Chemistry, Immunology and Laboratory Quality Control text frames case studies as a bridge between theoretical knowledge and clinical application. Similarly, the Manual of Veterinary Clinical Chemistry uses a case study approach to teach interpretation across species, demonstrating that this educational method transfers across diagnostic settings.

Peer-reviewed case exercises published through programs like Check Sample provide continuing education for laboratory professionals in clinical chemistry and related disciplines [12]. These exercises present real patient data with expected interpretation pathways, giving learners a structured way to test their diagnostic reasoning.

Core Principles for Result Interpretation

Reference Intervals Are Population Specific

Reference intervals are not universal constants. A Canadian Laboratory Initiative on Pediatric Reference Intervals study established pediatric reference intervals for 27 routine chemistry analytes on the Roche cobas pro platform and found that age-specific partitions were required for 23 of 27 analytes [14]. Electrolytes such as sodium and chloride remained stable across all ages, while analytes influenced by growth, bone metabolism, liver function, and muscle mass showed marked age and sex variation [14].

For adult patients, population-based reference intervals may obscure individual variation. A study of 45 healthy adults sampled weekly for six weeks found that personalized reference intervals were generally narrower than population-based intervals, with 94.7 percent of reference interval index values below 1 [15]. Liver enzymes, albumin, creatinine, ferritin, thyroid hormones, and lipids demonstrated high individuality, meaning population-based intervals have limited applicability for serial monitoring of these analytes [15]. Iron, by contrast, showed low individuality, supporting the validity of population-based intervals for that measurand [15].

Renal Function Modifies Interpretation

Kidney function changes how results must be read. A prospective study of 300 women across four immunoassay platforms established that human chorionic gonadotropin reference values in menopausal women depend heavily on estimated glomerular filtration rate [18]. Proposed cutoffs were 10 IU/L for eGFR at or above 60 mL/min and 15 IU/L for eGFR between 15 and 59 mL/min, regardless of analytical method [18]. For patients with eGFR below 15 mL/min, assay-specific cutoffs ranged from 18 to 36 IU/L [18].

The same principle applies to other analytes. Human epididymal protein 4 in pleural fluid showed significant increases in benign disease only when eGFR fell below 30 mL/min/1.73 m² [19]. Using a single cutoff across all renal function levels would misclassify patients with reduced kidney function.

Analytical Performance Limits Interpretation

Every assay has measurable performance characteristics that constrain interpretation. The Laboratory Quality Management System Handbook from the World Health Organization emphasizes that quality control data must be reviewed before patient results are released. Imprecision, linearity, and method comparison studies establish the analytical measuring range within which results are reliable [14].

When pathological conditions produce values exceeding the linearity range, laboratories face a workflow decision. A study at the University Hospital of Padua reviewed 86 clinical chemistry assays and identified 15 analytes requiring manual dilution beyond predefined automated limits [16]. The implementation of upper reporting limits eliminated most manual dilutions, reduced costs, and improved turnaround time, with clinician feedback confirming the appropriateness of the new reporting rules [16]. Lactate dehydrogenase was the only analyte where oncologic follow-up required precise reporting, so manual dilution was not completely eliminated for that test [16].

Case Study One: Hyponatremia in a Postoperative Patient

Patient History

A 62 year old female presents with confusion and fatigue three days after elective abdominal surgery. Medications include an opioid analgesic and a proton pump inhibitor. Intravenous fluids administered during the postoperative period were hypotonic.

Laboratory Results

Interpretation Pathway

The first step is to confirm that the low sodium is not an artifact of measurement. Pseudohyponatremia can occur with severe hyperlipidemia or hyperproteinemia when using indirect ion selective electrodes. The normal glucose and creatinine help exclude hyperglycemia and renal failure as causes of factitious or dilutional hyponatremia.

The measured serum osmolality of 252 mOsm/kg confirms true hypotonic hyponatremia. The next branch in the decision tree assesses volume status. The urine sodium of 38 mmol/L with urine osmolality above 100 mOsm/kg suggests impaired renal water excretion instead of volume depletion.

The postoperative setting raises the possibility of syndrome of inappropriate antidiuretic hormone secretion triggered by pain, opioids, or pulmonary complications. The urine osmolality above serum osmolality supports this diagnosis. Hypotonic fluid administration in the setting of impaired free water excretion worsens the hyponatremia.

Decision Tree for Hyponatremia

1. Confirm low sodium with repeat measurement or alternate method
2. Measure serum osmolality to distinguish true hypotonic hyponatremia from pseudohyponatremia
3. Assess volume status through physical examination and urine sodium
4. Evaluate urine osmolality to determine if antidiuretic hormone is appropriately suppressed
5. Identify contributing medications, fluids, or underlying conditions
6. Correct sodium at a controlled rate to avoid osmotic demyelination

Management Considerations

The laboratory professional should flag the critical sodium value and document the confirmatory testing performed. The clinical team needs to know the rate of sodium correction, but the laboratory role is to provide accurate serial measurements and alert the team to rapid shifts. Professional escalation criteria include a sodium below 120 mmol/L, acute change in mental status, or evidence of hemolysis affecting the potassium result.

Case Study Two: Liver Enzyme Elevation in an Asymptomatic Patient

Patient History

A 45 year old male presents for routine health screening. He reports no symptoms but takes a statin for hyperlipidemia and occasional acetaminophen for headaches. He drinks alcohol socially, approximately two drinks per week.

Laboratory Results

Interpretation Pathway

The pattern shows isolated aminotransferase elevation with ALT greater than AST. The ratio of AST to ALT is below 1, which is typical of early hepatocellular injury instead of alcohol related liver disease, where the ratio often exceeds 1.5.

The normal ALP and bilirubin argue against cholestatic disease. The normal albumin and platelets suggest preserved synthetic function and no evidence of portal hypertension.

The differential diagnosis includes nonalcoholic fatty liver disease, medication effect, and viral hepatitis. The statin and acetaminophen are potential contributors. The social alcohol history is unlikely to explain this degree of elevation.

Decision Tree for Liver Enzyme Elevation

1. Confirm the elevation with repeat testing
2. Calculate the AST to ALT ratio
3. Assess synthetic function with albumin and prothrombin time
4. Evaluate for cholestasis with ALP, GGT, and bilirubin
5. Review medication history including over the counter products
6. Consider metabolic risk factors including obesity and diabetes
7. Order viral hepatitis serology if risk factors are present

Laboratory Considerations

The Laboratory Quality Management System Handbook emphasizes that hemolyzed specimens can falsely elevate AST and potassium. The laboratory should check the hemolysis index before reporting these results. If the specimen was drawn after a recent meal, lipemia could interfere with some assays.

The high individuality of liver enzymes means that a single result above the population reference interval may not indicate disease for a given patient [15]. Serial monitoring is more informative than a single measurement. The laboratory should recommend repeat testing and document the trend.

Case Study Three: Pleural Effusion with Elevated HE4

Patient History

A 70 year old female presents with progressive dyspnea and a right sided pleural effusion. She has a history of hypertension and chronic kidney disease stage 3 with eGFR of 35 mL/min/1.73 m². Thoracentesis is performed.

Laboratory Results

Interpretation Pathway

The pleural fluid protein to serum protein ratio is 0.56 and the lactate dehydrogenase ratio is 1.17, meeting Light's criteria for an exudative effusion. The differential diagnosis for exudative effusions includes malignancy, infection, and inflammatory conditions.

The HE4 concentration of 2,450 pmol/L must be interpreted with renal function in mind. A study of 238 pleural fluid samples found that HE4 concentrations differed significantly between malignant and benign effusions, but patients with benign disease and eGFR below 30 mL/min/1.73 m² showed significant increases in HE4 [19]. For patients with eGFR above 30 mL/min/1.73 m², a cutoff of 1,992 pmol/L provided maximum specificity, while a cutoff of 3,050 pmol/L was needed for patients with eGFR below 30 mL/min/1.73 m² [19].

This patient has eGFR of 35 mL/min/1.73 m², placing her in the group where the 1,992 pmol/L cutoff applies. Her HE4 of 2,450 pmol/L exceeds this threshold, suggesting malignancy is possible. However, the sensitivity of HE4 in pleural fluid is low, so a negative result does not exclude malignancy [19].

Decision Tree for Pleural Effusion

1. Classify the effusion as transudate or exudate using Light's criteria
2. Assess renal function before interpreting biomarkers
3. Apply renal function adjusted cutoffs for HE4
4. Consider cytology, which diagnoses only 20 to 50 percent of malignant effusions [19]
5. Evaluate adenosine deaminase for tuberculous pleuritis
6. Correlate with imaging and clinical presentation

Limitations and Escalation

The low sensitivity of HE4 means that cytology and biopsy remain essential for definitive diagnosis. The laboratory should report the eGFR adjusted interpretation alongside the HE4 result. If the clinical team requests HE4 without renal function data, the laboratory should request a serum creatinine to support interpretation.

Case Study Four: Ascites of Unknown Etiology

Patient History

A 58 year old male with a history of hepatitis C presents with increasing abdominal girth and lower extremity edema. He has no known cirrhosis diagnosis. Paracentesis is performed.

Laboratory Results

Interpretation Pathway

The serum ascites albumin gradient is calculated by subtracting the ascitic fluid albumin from the serum albumin. This patient has a gradient of 1.6 g/dL, which is above the 1.1 g/dL threshold that distinguishes portal hypertension related ascites from other causes [22].

A gradient of 1.6 g/dL with low total protein in the ascitic fluid is consistent with cirrhosis related ascites. The low cell count with only 15 percent polymorphonuclear cells does not meet criteria for spontaneous bacterial peritonitis, which typically requires an absolute polymorphonuclear count above 250 cells/µL.

The differential diagnosis of ascites review emphasizes that routine ascitic fluid analysis should include serum ascites albumin gradient, total protein concentration, cell count, and differential [22]. Optional testing includes cholesterol, fluid culture, cytology, tumor markers, lactate dehydrogenase, adenosine deaminase, triglyceride, amylase, glucose, and brain natriuretic peptide [22].

Decision Tree for Ascites

1. Calculate the serum ascites albumin gradient
2. Interpret the gradient in the context of total protein
3. Assess cell count and differential for infection
4. Consider optional testing based on clinical suspicion
5. Evaluate for malignancy if gradient is low or cytology is requested
6. Correlate with liver function tests and imaging

Laboratory Considerations

The Laboratory Quality Management System Handbook requires that specimen collection and handling procedures be documented. Ascitic fluid should be collected in appropriate tubes for cell count, chemistry, and culture. The time between collection and analysis affects cell viability and glucose results.

The laboratory should verify that the serum and fluid specimens were collected concurrently, as the gradient calculation depends on simultaneous measurement. Delayed serum collection can alter the gradient and lead to misclassification.

Case Study Five: Anemia with Abnormal Iron Studies

Patient History

A 34 year old female presents with fatigue, pallor, and shortness of breath on exertion. She reports heavy menstrual bleeding. Physical examination reveals pale conjunctivae.

Laboratory Results

Interpretation Pathway

The microcytic hypochromic anemia with elevated red cell distribution width points toward iron deficiency. The ferritin of 8 ng/mL is below the reference interval and confirms depleted iron stores. Transferrin saturation below 10 percent supports the diagnosis.

An algorithm for the differential diagnosis of anemia developed for clinical pathologists and laboratory medicine physicians emphasizes the efficient use of gold standard diagnostic tests and calculated indices [24]. The algorithm addresses overuse of screening tests and misinterpretation of studies, which can lead to late diagnoses and missed treatment opportunities [24].

The differential diagnosis for microcytic anemia includes iron deficiency, thalassemia trait, and anemia of chronic disease. The ferritin result distinguishes iron deficiency from the other causes. In the presence of inflammation, ferritin can be falsely elevated, so a normal ferritin does not exclude iron deficiency in patients with chronic disease.

Decision Tree for Microcytic Anemia

1. Confirm the anemia with repeat complete blood count
2. Calculate red cell indices and red cell distribution width
3. Measure ferritin, iron, total iron binding capacity, and transferrin saturation
4. Consider hemoglobin electrophoresis if thalassemia is suspected
5. Evaluate for sources of blood loss
6. Assess for inflammation that could affect ferritin interpretation

Laboratory Considerations

Ferritin is an acute phase reactant. The Laboratory Quality Management System Handbook notes that quality control materials must be validated for each assay. The laboratory should flag the critical low hemoglobin and recommend immediate clinical review.

The high individuality of ferritin means that population reference intervals may not capture an individual patient's baseline [15]. Serial monitoring of ferritin during iron replacement therapy is more informative than a single measurement.

Case Study Six: Lung Cancer Biomarker Evaluation

Patient History

A 66 year old male with a 40 pack year smoking history presents with a pulmonary nodule found on computed tomography. He is asymptomatic. Serum biomarkers are ordered to support the diagnostic workup.

Laboratory Results

Interpretation Pathway

The Siaα-2,6Gal level of 2,750 U/mL is elevated compared to the median of 2,606 U/mL observed in a lung cancer group and well above the median of 1,419 U/mL observed in a benign pulmonary nodule group [20]. A multicenter study of 730 patients and 120 healthy individuals found that Siaα-2,6Gal had a high diagnostic efficiency for lung cancer with an area under the curve of 0.9217, significantly superior to carcinoembryonic antigen, CYFRA21-1, squamous cell carcinoma antigen, neuron specific enolase, and ProGRP [20].

The traditional biomarkers are all within their reference intervals, which illustrates the limitation of these markers for early detection. The study found that Siaα-2,6Gal levels in early stage lung cancer were significantly higher than in benign pulmonary nodules, suggesting a role in differential diagnosis [20].

Decision Tree for Lung Cancer Biomarkers

1. Confirm the nodule characteristics on imaging
2. Order a panel of biomarkers including Siaα-2,6Gal
3. Interpret Siaα-2,6Gal in the context of the traditional markers
4. Consider biopsy for definitive diagnosis
5. Use biomarkers for monitoring after treatment if elevated at baseline

Limitations and Escalation

Biomarkers cannot replace tissue diagnosis. The laboratory should report Siaα-2,6Gal with a note that this is an emerging marker and that clinical correlation is required. The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides guidance on assay development and validation for emerging biomarkers.

Case Study Seven: Cholangiocarcinoma Differential Diagnosis

Patient History

A 72 year old male presents with jaundice, pruritus, and weight loss. Magnetic resonance cholangiopancreatography shows a hilar stricture. Bile samples are collected during endoscopic retrograde cholangiopancreatography.

Laboratory Results

Interpretation Pathway

Volatile organic compounds in bile may serve as diagnostic biomarkers for perihilar cholangiocarcinoma. A study of 200 bile samples from patients with perihilar cholangiocarcinoma and benign biliary diseases detected 19 volatile organic compounds using gas chromatography ion mobility spectrometry [21]. Three new volatile organic compounds were identified in bile: 2-methoxyfuran, propyl isovalerate, and diethyl malonate [21].

Twelve volatile organic compounds showed significant differences between benign biliary disease and perihilar cholangiocarcinoma, including four upregulated compounds in cholangiocarcinoma: 2-ethyl-1-hexanol, propyl isovalerate, cyclohexanone, and acetophenone [21]. Machine learning models based on volatile organic compound spectra achieved an area under the curve of 0.966 with a support vector machine, providing 93.1 percent sensitivity and 100 percent specificity [21].

Decision Tree for Biliary Stricture

1. Obtain bile samples during endoscopic retrograde cholangiopancreatography
2. Analyze volatile organic compounds using gas chromatography ion mobility spectrometry
3. Apply machine learning models for classification
4. Correlate with cytology and histology
5. Consider this approach as an adjunct to tissue diagnosis

Laboratory Considerations

Volatile organic compound analysis requires specialized instrumentation and analytical validation. The Bioanalytical Method Validation Guidance from the U.S. Food and Drug Administration provides a framework for validating analytical methods used to measure analytes in biological matrices. The laboratory must document preanalytical variables including collection container, storage temperature, and time to analysis.

Case Study Eight: Diabetic Kidney Disease versus Non-Diabetic Kidney Disease

Patient History

A 60 year old male with type 2 diabetes for 12 years presents with chronic kidney disease. Urine albumin to creatinine ratio is 300 mg/g. Renal biopsy is planned to distinguish diabetic kidney disease from non-diabetic kidney disease.

Laboratory Results

Interpretation Pathway

A study of 132 type 2 diabetic patients with chronic kidney disease categorized patients into diabetic kidney disease and non-diabetic kidney disease groups based on renal biopsy [23]. Serum neutrophil gelatinase associated lipocalin was identified as an independent risk factor for diabetic kidney disease [23]. Tubular biomarkers including serum NGAL, N-acetyl-β-D-glucosaminidase, and β2-microglobulin complemented albuminuria for diabetic kidney disease detection with an area under the curve of 0.926, specificity of 90.14 percent, and sensitivity of 80.33 percent [23].

The elevated serum NGAL and β2-microglobulin in this patient support the presence of tubular injury. The model for predicting unfavorable renal outcomes included serum NGAL, interstitial fibrosis and tubular atrophy score, β2-microglobulin, and eGFR [23].

Decision Tree for Diabetic Kidney Disease

1. Confirm diabetes duration and glycemic control
2. Measure urine albumin to creatinine ratio
3. Assess tubular biomarkers including serum NGAL and β2-microglobulin
4. Consider renal biopsy for definitive classification
5. Apply the prognostic model for end stage renal disease risk
6. Monitor renal function serially

Laboratory Considerations

The Laboratory Quality Management System Handbook requires that the laboratory document the analytical performance of each assay. Serum NGAL is not a routine test in most laboratories, so the laboratory must validate the assay before reporting results. The high individuality of creatinine and related renal markers supports the use of serial monitoring instead of single measurements [15].

Quality Control and Preanalytical Variables

Specimen Collection and Handling

The Laboratory Biosafety Manual from the World Health Organization provides guidance on safe handling of biological specimens. Laboratory professionals must follow standard precautions when processing blood, pleural fluid, ascitic fluid, and bile samples.

Hemolysis, lipemia, and icterus can interfere with spectrophotometric assays. The laboratory should document the hemolysis index for each specimen and flag results that may be affected. For example, hemolysis falsely elevates AST, lactate dehydrogenase, and potassium.

Analytical Quality Control

The Laboratory Quality Management System Handbook describes the components of a quality management system including quality control, quality assessment, and continuous improvement. Internal quality control materials should be run at defined intervals to verify assay performance. External quality assessment programs compare results across laboratories.

The Bioanalytical Method Validation Guidance from the U.S. Food and Drug Administration outlines the validation parameters required for quantitative analytical methods, including accuracy, precision, selectivity, sensitivity, reproducibility, and stability. These principles apply to clinical chemistry assays as well as research methods.

Reporting and Critical Values

The laboratory must define critical values that require immediate notification of the clinical team. Examples include sodium below 120 mmol/L, potassium above 6.0 mmol/L, glucose below 50 mg/dL, and calcium above 13 mg/dL. The Laboratory Quality Management System Handbook emphasizes that critical value policies must be documented and followed consistently.

Common Failure Patterns in Result Interpretation

Overreliance on Population Reference Intervals

Population reference intervals can mislead when applied to individual patients. The study on personalized reference intervals found that liver enzymes, albumin, creatinine, ferritin, thyroid hormones, and lipids demonstrated high individuality, meaning that a result within the population interval may still represent a significant change for a given patient [15]. Serial monitoring with personalized baselines is more informative for these analytes.

Ignoring Renal Function

Renal function modifies the interpretation of many analytes. The hCG study demonstrated that reference values in menopausal women depend on eGFR, with cutoffs ranging from 10 IU/L for preserved renal function to 36 IU/L for end stage renal disease [18]. The HE4 study showed that renal function adjusted cutoffs improve specificity in pleural fluid [19]. Laboratories should report eGFR alongside creatinine and flag results that require renal function adjusted interpretation.

Applying Adult Reference Intervals to Pediatric Patients

Pediatric reference intervals differ substantially from adult intervals. The CALIPER study found that age-specific partitions were required for 23 of 27 routine chemistry analytes [14]. Analytes influenced by growth, bone metabolism, liver function, and muscle mass demonstrated marked age and sex variation [14]. Laboratories serving pediatric populations must use age appropriate reference intervals.

Failing to Confirm Critical Results

Critical results should be confirmed before reporting. The Laboratory Quality Management System Handbook requires that the laboratory have a policy for repeat testing of critical values. Confirmation may involve repeating the assay on the same specimen or requesting a new specimen.

Misinterpreting Biomarker Sensitivity

Biomarkers with high specificity often have low sensitivity. HE4 in pleural fluid demonstrated high specificity but low sensitivity for malignancy [19]. A negative HE4 does not exclude malignancy, and cytology remains essential. Similarly, volatile organic compound models for cholangiocarcinoma require specialized instrumentation and validation before clinical use [21].

Professional Escalation Criteria

Laboratory professionals should escalate findings to the clinical team when:

1. A critical value is identified that requires immediate action
2. Results are inconsistent with the clinical presentation
3. Preanalytical variables may have affected the result
4. Renal function adjusted interpretation changes the clinical conclusion
5. Serial results show unexpected trends that may indicate assay drift
6. Quality control failures suggest unreliable results

The Laboratory Quality Management System Handbook describes the laboratory's responsibility to communicate effectively with clinicians. Documentation of the communication, including the time, date, and person notified, is essential for patient safety and legal protection.

Records and Documentation

What to Record

The laboratory should document for each case:

1. Patient identifiers and demographic data
2. Specimen type, collection time, and receipt time
3. Preanalytical variables including hemolysis, lipemia, and icterus indices
4. Analytical method and instrument used
5. Quality control results for the run
6. Reference intervals applied and their source
7. Any repeat testing or dilution performed
8. Critical value notifications with time and recipient
9. Interpretation notes and clinical correlation

How to Use Records for Education

Case records can be anonymized and used for teaching. The Check Sample program publishes peer reviewed case studies for continuing education in clinical chemistry and related disciplines [12]. These cases help laboratory professionals practice interpretation skills and stay current with diagnostic approaches.

Safety Context for Laboratory Work

The Laboratory Biosafety Manual from the World Health Organization provides guidance on risk assessment, standard precautions, and safe handling of biological materials. Laboratory professionals working with blood, pleural fluid, ascitic fluid, and bile must:

1. Wear appropriate personal protective equipment including gloves and laboratory coats
2. Handle needles and sharps with caution
3. Decontaminate work surfaces after each procedure
4. Follow waste disposal procedures for biological materials
5. Report exposures immediately to the designated safety officer

The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides additional guidance on assay development and validation that supports reliable results.

Frequently Asked Questions

How do I determine if a low sodium result is real or an artifact?

Measure serum osmolality to distinguish true hypotonic hyponatremia from pseudohyponatremia. Pseudohyponatremia occurs with severe hyperlipidemia or hyperproteinemia when using indirect ion selective electrodes. A normal measured osmolality with a low sodium suggests artifact. The Laboratory Quality Management System Handbook emphasizes confirming critical results before reporting.

Why do reference intervals differ between pediatric and adult patients?

Pediatric reference intervals reflect rapid physiological changes during growth and development. A CALIPER study found that age-specific partitions were required for 23 of 27 routine chemistry analytes on the Roche cobas pro platform [14]. Electrolytes such as sodium and chloride remained stable, while analytes influenced by growth, bone metabolism, liver function, and muscle mass showed marked age and sex variation [14].

When should I use renal function adjusted cutoffs for biomarkers?

Use renal function adjusted cutoffs when the biomarker is cleared by the kidney or when published evidence supports stratification by eGFR. For human chorionic gonadotropin in menopausal women, proposed cutoffs were 10 IU/L for eGFR at or above 60 mL/min and 15 IU/L for eGFR between 15 and 59 mL/min [18]. For HE4 in pleural fluid, different cutoffs apply depending on whether eGFR is above or below 30 mL/min/1.73 m² [19].

What is the serum ascites albumin gradient and how do I interpret it?

The serum ascites albumin gradient is calculated by subtracting the ascitic fluid albumin from the serum albumin. A gradient above 1.1 g/dL indicates portal hypertension related ascites, while a lower gradient suggests other causes [22]. Routine ascitic fluid analysis should include the gradient, total protein, cell count, and differential [22].

How do I interpret liver enzyme elevations in an asymptomatic patient?

Calculate the AST to ALT ratio, assess synthetic function with albumin and prothrombin time, and evaluate for cholestasis with ALP, GGT, and bilirubin. Review medication history including over the counter products. Liver enzymes have high individuality, so serial monitoring is more informative than a single measurement [15].

What biomarkers are useful for lung cancer differential diagnosis?

Siaα-2,6Gal demonstrated high diagnostic efficiency for lung cancer with an area under the curve of 0.9217, superior to carcinoembryonic antigen, CYFRA21-1, squamous cell carcinoma antigen, neuron specific enolase, and ProGRP [20]. However, biomarkers cannot replace tissue diagnosis, and emerging markers require clinical correlation.

How do I distinguish diabetic kidney disease from non-diabetic kidney disease?

Tubular biomarkers including serum neutrophil gelatinase associated lipocalin, N-acetyl-β-D-glucosaminidase, and β2-microglobulin can complement albuminuria for diabetic kidney disease detection [23]. Renal biopsy remains the gold standard for classification. A prognostic model including serum NGAL, interstitial fibrosis and tubular atrophy score, β2-microglobulin, and eGFR can predict unfavorable renal outcomes [23].

What should I do when a result exceeds the linearity range of the assay?

Follow the laboratory's dilution protocol or report the result to a defined cutoff when exact values are not required for patient management. A study at the University Hospital of Padua implemented upper reporting limits for 15 analytes, eliminating most manual dilutions and improving turnaround time [16]. Lactate dehydrogenase was the only analyte where precise reporting was required for oncologic follow-up [16].

Related Diagnostic Guides

• Multiplex Real-Time RT-PCR for Differential Diagnosis of Canine Infectious Respiratory Disease Complex (CIRDC): Panel Design, Validation, and Clinical Utility
• CRISPR-Cas12a-Based Nucleic Acid Detection for Rapid Diagnosis of Canine Distemper Virus in Clinical Samples
• Multiplex RT-qPCR for Differential Diagnosis of Canine Respiratory Pathogens: Panel Design, Analytical Sensitivity, and Clinical Application
• Establishing Reference Intervals in Veterinary Clinical Chemistry
• Negative Controls in ELISA: Setup and Interpretation for Reliable Results

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Antibody-Drug Conjugates-A Tutorial Review.. Molecules (Basel, Switzerland), 2021.
• Artificial intelligence in antibody-drug conjugate development.. Trends in pharmacological sciences, 2025.
• Overcoming Challenges in the Metabolism of Peptide Therapeutics: Strategies and Case Studies for Clinical Success.. Journal of medicinal chemistry, 2025.
• Case-based studies in teaching medicinal chemistry in PharmD curriculum: Perspectives of students, faculty, and pharmacists from academia.. Currents in pharmacy teaching & learning, 2018.
• The Importance of Medicinal Chemistry Knowledge in the Clinical Pharmacist's Education.. American journal of pharmaceutical education, 2018.
• Structural Simplification of Natural Products.. Chemical reviews, 2019.
• Check Sample Abstracts.. American journal of clinical pathology, 2009.
• Clinical Applications of Targeted Nanomaterials.. Pharmaceutics, 2025.
• Pediatric reference intervals for 27 routine chemistry analytes in healthy children and adolescents on the Roche cobas pro platform.. 2026.
• Personalized reference intervals for biochemical, hormonal, and coagulation tests: Comparison with population-based reference intervals.. 2026.
• A model to increase automation and support reliable interpretation of clinical chemistry tests.. 2026.
• A systematic DoE approach for optimizing urinary LC-HRMS metabolomics: enhancing reliability in bladder cancer profiling.. 2026.
• Serum hCG reference values in menopausal women across four immunoassay platforms: implications of renal function for clinical interpretation.. 2026.
• The diagnostic accuracy of HE4 in the differential diagnosis of pleural effusions.. Clinica chimica acta, international journal of clinical chemistry, 2024.
• Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer.. Clinica chimica acta, international journal of clinical chemistry, 2024.
• Identification and validation of volatile organic compounds in bile for differential diagnosis of perihilar cholangiocarcinoma.. Clinica chimica acta, international journal of clinical chemistry, 2023.
• Differential diagnosis of ascites: etiologies, ascitic fluid analysis, diagnostic algorithm. Clinical Chemistry and Laboratory Medicine, 2023.
• The Role of Tubulointerstitial Markers in Differential Diagnosis and Prognosis in Patients with Type 2 Diabetes and Biopsy Proven Diabetic Kidney Disease.. Clinica chimica acta, international journal of clinical chemistry, 2023.
• Algorithm of differential diagnosis of anemia involving laboratory medicine specialists to advance diagnostic excellence. Clinical Chemistry and Laboratory Medicine, 2023.
• Manual of Veterinary Clinical Chemistry: A Case Study Approach. Manual of Veterinary Clinical Chemistry A Case Study Approach, 2010.
• Clinical Chemistry, Immunology and Laboratory Quality Control: A Comprehensive Review for Board Preparation, Certification and Clinical Practice. Clinical Chemistry Immunology and Laboratory Quality Control A Comprehensive Review for Board Preparation Certification and Clinical Practice, 2021.
• Harmonizing analytical chemistry and clinical epidemiology for human biomonitoring studies. A case-study of plastic product chemicals in urine. Chemosphere, 2020.
• Evaluation of computerized medicinal chemistry case study modules as tools to enhance student learning and clinical problem-solving skills. American Journal of Pharmaceutical Education, 1999.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.